Harrison Gunn is a senior associate in Goodwin's Intellectual Property Litigation group where he focuses his practice on patent matters spanning technologies in the pharmaceutical, electronic, and mechanical arts. Harrison's experience includes trials before state and federal district courts, appeals before the Federal Circuit, post-grant proceedings before the Patent Trial and Appeal Board, Section 337 Investigations before the International Trade Commission, and confidential arbitrations. Harrison is a contributor to the firm’s Big Molecule Watch, an award-winning blog that reports real-time analysis and updates on regulatory issues, litigation, legislation, and other news in the developing world of biosimilars. He is also an editor of the firm’s PTAB Trial Tracker, a newsletter that publishes regular updates on legal developments related to post-grant proceedings. Harrison also provides pro bono representation on immigration matters helping unaccompanied children obtain permanent resident status.
Professional Experience
In law school, Harrison assisted clients with biotechnology and nanotechnology related products through the Detkin Intellectual Property and Technology Legal Clinic. He was also an editor of the Journal of Law & Innovation and the Journal of Business Law and was a President of the Penn Intellectual Property Group. Harrison received a Certificate in Engineering Entrepreneurship from the School of Engineering and Applied Science at the University of Pennsylvania concurrent with his legal studies.
In 2024, Harrison completed a six-month rotation as a Special Assistant District Attorney in Middlesex County at Lowell District Court where he brought five cases to trial—two jury trials and three bench trials—and was able to obtain guilty verdicts on both jury trials and all but one of the bench trials. Harrison also argued dozens of evidentiary and non-evidentiary motions including motions to dismiss, motions to suppress, and other discovery related motions.
- United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del.): Represented plaintiff pharmaceutical company in bench trial regarding patent litigation related to manufacturing methods and methods of administering inhaled treprostinil. Achieved favorable trial opinion.
- Hoffman-la Roche, Inc., et al v. Fresenius Kabi USA, LLC (D. Del): Represented ANDA-defendant pharmaceutical company in patent litigation related to generic alectinib products. The case settled favorably prior to trial.
- Otsuka Pharmaceutical Co. Ltd. v. Teva Pharmaceuticals Inc. et al (D. Del.): Represented ANDA-defendant pharmaceutical company in patent litigation related to generic tolvaptan products. The case settled favorably prior to trial.
- Pacira Pharmaceuticals, Inc. et al v. eVenus Pharmaceuticals Laboratories, Inc. et al (D. N.J.): Represented ANDA-defendant pharmaceutical company in bench trial regarding patent litigation related to generic liposomal bupivacaine products. Achieved favorable trial opinion.
- United Therapeutics Corporation v. Liquidia Technologies, Inc. (D. Del.): Represent plaintiff pharmaceutical company in patent litigation related to improving exercise capacity in PH-ILD patients with inhaled treprosintil. Ongoing.
- Mobile Data Technologies LLC v. Samsung Electronics America, Inc. et al (E.D. Tex.): Represent electronics company in patent litigation related to sharing content with mobile devices. Ongoing.
- Exela Pharma Sciences, LLC v. Dr. Reddy’s Laboratories S.A. (No. 23-1026): Represented appellant pharmaceutical company and ANDA-defendant following adverse finding in District Court over patent litigation involving generic L-cystine products. Case settled favorably following opening appellate brief.
- Incyte Corporation v. Sun Pharmaceutical Industries, Inc. (No. 23-1300): Represent appellee pharmaceutical company following favorable finding in PGR upholding patentability of challenged patent directed to treating hair loss disorders with deuterated ruxolitinib. Ongoing.
- Acorda v. Alkermes (AAA arbitration): Represented brand pharmaceutical company in dispute raising claims for antitrust, breach of contract, and patent misuse related to license and supply agreements. Achieved favorable award.
- Certain Polycrystalline Diamond Compacts And Articles Containing Same (Inv. No. 337-TA-1236): Represented respondent drill bit manufacturers in 337 investigation involving patents directed to polycrystalline diamond compacts. Achieved favorable initial determination.
- Certain Filament Light-Emitting Diodes and Products Containing Same (II) (Inv. No. 337-TA-1220): Represented respondent lightbulb companies in 337 investigation involving patents directed to light emitting diodes. Achieved favorable initial determination.
- Certain Outdoor and Semi-Outdoor Electronic Displays, Products Containing Same, and Components Thereof (Inv. No. 337-TA-1331): Represented respondent electronics company in 337 investigation involving patents directed to cooling systems for outdoor displays. Achieved favorable initial determination.
- Incyte Corporation v. Concert Pharmaceuticals, Inc. (PGR2021-00006): Represented patent owner pharmaceutical company in post-grant review of patent directed to treating hair loss disorders with deuterated ruxolitinib. Achieved final written decision upholding patentability of all challenged claims.
Credentials
Education
JD2020
University of Pennsylvania Law School
BSChemical Engineering2017
Syracuse University
Admissions
Bars
- Massachusetts
Courts
- U.S. District Court for the District of Massachusetts
- U.S. Court of Appeals for the Federal Circuit